TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03184467

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 0.9%
Description: Normal saline 0.9% is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV1001 0.56 mg
Description: GV1001 0.56 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV1001 1.12 mg
Description: GV1001 1.12 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
Study: NCT01330758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD8931
Description: 40 mg AZD8931 wet granulation tablet formulation
Study: NCT04122339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAX-10181
Description: Part 1: Dose escalation, MAX-10181 once or twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1.
Study: NCT04411030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: Form: capsule; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: Form: capsule; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Form: syrup; Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Form: capsule; Route of administration: oral
Study: NCT04831255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide extended-release injectable suspension
Description: ZILRETTA (triamcinolone acetonide extended-release injectable suspension) injection in the glenohumeral joint administered under ultrasound guidance.
Study: NCT03996694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belbuca 300 µg
Description: Belbuca 300 µg buccal film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belbuca 600 µg
Description: Belbuca 600 µg buccal film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belbuca 900 µg
Description: Belbuca 900 µg buccal film

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone 30 mg
Description: Oxycodone 30 mg capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone 60 mg
Description: Oxycodone 60 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo buccal film and oral placebo
Study: NCT03441373

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XC8 20 mg
Description: once daily during 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8 20 mg
Description: once daily during 5 days.
Study: NCT01330758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8931
Description: 40 mg AZD8931 roller compacted tablet formulation
Study: NCT01179971

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil, gamma-linolenic acid
Description: 3 g/d DHA + EPA

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil, gamma-linolenic acid
Description: 3 g/d DHA + EPA

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil, gamma-linolenic acid
Description: 3 g/d DHA + EPA

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Fish oil, gamma-linolenic acid
Description: 3 g/d DHA + EPA
Study: NCT00095758

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antidepressant + Placebo
Description: Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antidepressant + Aripiprazole
Description: Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
Study: NCT00184015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab and Bortezomib
Description: Bevacizumab 15 mg/kg on day 1 with Bortezomib 1.0 or 1.3 mg/m2 on days 1, 4, 8 and 11 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab and Bortezomib
Description: Bevacizumab 15 mg/kg on day 1 with Bortezomib 1.6 or 1.8 mg/m2 on days 1 and 8 every 21 days
Study: NCT01356433

Intervention type: DRUG
Group type: OTHER
Intervention: oral vitamin C
Description: cross-over study,2 arms Arm 1(50cases): is given oral vitamin C 200mg per day in the first 3 months, then stop oral VitC for the next 3 months.~Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months.

Intervention type: DRUG
Group type: OTHER
Intervention: oral vitamin C
Description: cross-over study,2 arms Arm 1(50cases): is given oral vitamin C 200mg per day in the first 3 months, then stop oral VitC for the next 3 months.~Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months.
Study: NCT04033055

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inguinal hernia repair with CycloMesh™ soaked in ropivacaine hydrochloride 10mg/mL
Description: The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).~CycloMesh™ device (soaked in ropivacaine hydrochloride 10mg/mL) is positioned once the surgery for the inguinal hernia repair has been performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal hernia repair with CycloMesh™ soaked in saline solution NaCl 9°/°°
Description: The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).~CycloMesh™ device (soaked in saline solution) is positioned once the surgery for the inguinal hernia repair has been performed.
Study: NCT04585204

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose tolerance test
Description: Oral glucose tolerance test

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose tolerance test
Description: Oral glucose tolerance test
Study: NCT02161835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: 30 minutes of home based pulse watch regulated cycle-ergometer exercise, three times a week at 75% of maximal oxygen consumption.
Study: NCT04463342

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Non Coated Glass Ionomer
Description: KetacTM Universal AplicapTM Glass Ionomer Restorative saves time by eliminating the need for a coating-yet still delivers the compressive strength and surface hardness that are higher than several competitive glass ionomers which require one.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Glass Ionomer with Coat
Description: Conventional Glass Ionomer with Coat
Study: NCT02402582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family-centered empowerment model
Description: FCEM and Control groups had similar inpatient care. Patients in the intervention group received care employing the FCEM in four stages. Stage 1: Awareness and cognition. During 3-5 group sessions they were evaluated for their insight into their perceived illness severity and perceived sensitivity, or the degree to which they felt threatened by their illness. Stage 2: Expectations. 3-5 sessions. Stage 3: Acceptance. Assessed using an educational participation method in group discussion. Stage 4: Formative summative evaluations. The formative evaluation encourages patients to internalize their locus of control by seeing his/her self-empowerment (increasing self-responsibility about their health). Summative evaluations were performed to evaluate the influence of the intervention on HRQoL dimensions, perceived stress and anxiety -- assessed at baseline and at 3 months post-intervention. Empowerment was measured at baseline and at 10 days post-intervention by deploying FCEM questionnaires.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: FCEM and Control groups had similar inpatient care. Upon discharge the Control group underwent routine care and follow-up.
Study: NCT03158324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPB-111077
Description: Receive 600 mg of OPB-111077 on a 4 days-on, 3 days-off per week in 28-day cycles till disease progression or intolerable toxicity
Study: NCT00350688

Intervention type: RADIATION
Group type: OTHER
Intervention: Helical tomotherapy IMRT
Description: Helical tomotherapy IMRT
Study: NCT04698603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Methoxy N,N Dimethyltryptamine
Description: GH001 administered via inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Methoxy N,N Dimethyltryptamine
Description: GH001 administered via inhalation
Study: NCT03441373

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XC8 100 mg
Description: once daily during 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8 100 mg
Description: once daily during 5 days.
Study: NCT04698603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Methoxy N,N Dimethyltryptamine
Description: GH001 administered via inhalation
Study: NCT01356433

Intervention type: DRUG
Group type: OTHER
Intervention: oral vitamin C
Description: Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months.

Intervention type: DRUG
Group type: OTHER
Intervention: oral vitamin C
Description: Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months.
Study: NCT02969928

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full-mouth ultrasonic debridement
Description: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full-mouth ultrasonic debridement
Description: Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
Study: NCT02837029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium Y 90 Glass Microspheres
Description: Given IA
Study: NCT03441373

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XC8 200 mg
Description: once daily during 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8 200 mg
Description: once daily during 5 days.
Study: NCT01817426

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02128724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: Buparlisib is a highly specific inhibitor of phosphatidylinositol 3-kinase (PI3K). Buparlisib is supplied as 10mg and 50mg hard gelatin capsules.
Study: NCT02780492

Intervention type: OTHER
Intervention: Set of assessment tools

Intervention type: OTHER
Intervention: Set of assessment tools

Intervention type: OTHER
Intervention: Set of assessment tools
Study: NCT06088719

Intervention type: PROCEDURE
Intervention: axillary surgery
Description: one group undergoes axillary surgery
Study: NCT04994756

Intervention type: PROCEDURE
Intervention: Stroke/Thrombectomy/Aneurysm-specific surgical procedures
Description: Participants are retrospectively and/or prospectively entered into registry based on disease indication and respective surgical procedure.

Intervention type: PROCEDURE
Intervention: Stroke/Thrombectomy/Aneurysm-specific surgical procedures
Description: Participants are retrospectively and/or prospectively entered into registry based on disease indication and respective surgical procedure.

Intervention type: PROCEDURE
Intervention: Stroke/Thrombectomy/Aneurysm-specific surgical procedures
Description: Participants are retrospectively and/or prospectively entered into registry based on disease indication and respective surgical procedure.
Study: NCT03535129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real time fMRI neurofeedback
Description: During fMRI study, display feedback of brain activity to practice and reinforce control of alcohol craving.
Study: NCT03213288

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Delphinidin type anthocyanins
Description: Bilberry extract containing Delphinidin type anthocyanins

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cyanidin type anthocyanins
Description: Black rice extract containing Cyanidin type anthocyanins

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No anthocyanins
Study: NCT01159015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KetoNaph
Description: Ophthalmic Solution administered BID for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle of KetoNaph ophthalmic solution administered bid for six weeks
Study: NCT02639442

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearRing™
Study: NCT00933322

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: diet enriched with industrial trans fatty acids
Description: After run-in phase of 2 weeks with margarine without TFA, 4 weeks with margarine enriched with industrial trans fatty acids following. TFA-percentage of total energy consumption is 2% or 6% of total fat energy consumption.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: diet enriched with ruminant trans fatty acids
Description: After run-in phase of 2 weeks with margarine without TFA, 4 weeks with butter enriched with ruminant trans fatty acids following. TFA-percentage of total energy consumption is 2% or 6% of total fat energy consumption.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: diet without any trans fatty acids
Description: 6 weeks with margarine without any trans fatty acids.
Study: NCT01974622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visudyne
Description: Half fluence verteporfin
Study: NCT03506997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg given as a 30 minute intravenous (IV) infusion, on day 1 of each 3 week cycle. Patients may continue with pembrolizumab treatment as long as they remain free from intolerable toxicity for a maximum of two years, if in the Investigator's opinion they are receiving clinical benefit, and/or they do not meet any discontinuation criteria.
Study: NCT02984917

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior transversalis fascia approach
Description: Patients will undergo inguinal hernia repair via the anterior transversalis fascia approach.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preperitoneal space approach
Description: Patients will undergo inguinal hernia repair via the preperitoneal space approach.
Study: NCT00413036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: once daily oral capsule
Study: NCT03539718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taurolidine heparin
Description: Taurolock-hep 500 at end of session

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin Sodium
Description: Heparin sodium 5000 at end of session
Study: NCT00394706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impedance Threshold Device (ITD)
Description: Use of Impedance Threshold Device (ITD)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham ITD
Description: Sham ITD

Intervention type: OTHER
Group type: OTHER
Intervention: Analyze early
Description: Upon EMS arrival at the scene of a non-traumatic cardiac arrest, an assessment of the cardiac rhythm is done to determine whether a defibrillatory shock is required.

Intervention type: OTHER
Group type: OTHER
Intervention: Analyze later
Description: Upon EMS arrival at the scene of a non-traumatic cardiac arrest, three minutes of CPR is given prior to the assessment of the cardiac rhythm to determine whether a defibrillatory shock is required.
Study: NCT04094857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBN-1
Description: Intravenous infusion
Study: NCT01649934

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation Intention
Description: Implementation Intentions are a series of what/when/where statements that a participant will make to create automatic cues to complete a behaviorally advantageous action.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contact Clinic
Description: Participants will be asked to sign a form indicating their need to contact the recommended clinics to make their appointments.
Study: NCT03737539

Intervention type: DIAGNOSTIC_TEST
Intervention: Multigene methylation detection
Description: Colorectal tumor-specific plasma ctDNA methylation markers detection
Study: NCT03316638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: W0101 - Cohort A1
Description: Administered once every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: W0101 - Cohort A2
Description: Administered every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: W0101 - Expansion Phase
Description: Administered according to the recommended dose for expansion
Study: NCT01247961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone acetate
Description: 10 mg intravenous given as single administration with optional repeat dose after 36 hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT03441386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise Session
Study: NCT02473900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1403
Description: Oseltamivir 75mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1403
Description: Oseltamivir 75mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0919
Description: Oseltamivir phosphate 75mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0919
Description: Oseltamivir phosphate 75mg
Study: NCT01403155

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-3401 + EP
Description: All subjects will receive 0.9mg/mL of study vaccine (INO-3401 DNA plasmid vaccine)at Day 0 and Month 3.
Study: NCT02707146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visit Planner
Description: The Visit Planner is an application hosted on an iPad that guides the patient in preparing for the primary care visit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Pamphlet
Description: Patients in the attention control arm will receive an approved educational handout on health lifestyle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPad
Study: NCT02041845

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 45 Gy in 30 fractions
Description: 3D conformal thoracic radiotherapy at a total dose of 45 Gy in 30 fractions, 2 fractions per day, 5 days a week
Study: NCT02969928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Administration of Clarithromycin 500mg bid for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Administration of Amoxicillin 500mg tid for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Administration of Metronidazole 400mg tid for 7 days.
Study: NCT04409821

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-delivered psychological intervention
Description: The intervention consists of two (or one, if preferred by caregivers) weekly tele-sessions during the ICU stay, lasting up to 30 minutes, and two sessions in the month after discharge from or death in the ICU. Sessions will be conducted via phone-calls or video-conferencing. Therapists will 1) validate caregivers' subjective experience, 2) normalize and psychoeducate about emotional reactions, and 3) offer emotion regulation drawing on contemporary cognitive treatment packages of decentering, acceptance and emotion tolerance. Sessions for bereaved caregivers will include psycho-education about grief, assessment of risk for adverse outcomes and information about available support, if needed. The intervention will be performed based on an intervention manual. The content of the intervention will be continually adapted and tailored to the needs of the participating caregivers by involving all caregivers in co-creating the intervention trough brief post-session interviews.
Study: NCT03108248

Intervention type: DRUG
Intervention: ethiodized oil; doxorubicin;Gelfoam;
Description: Conventional TACE was performed in both groups as follows. First, multiple angiographies were performed to detect the hepatic arterial anatomy and the possible feeding arteries of tumor, selective catheterization of the artery feeding the tumors was performed. A mixture of ethiodized oil was injected, followed by injection of Gelfoam particles.

Intervention type: DRUG
Intervention: ethiodized oil; doxorubicin;Gelfoam;
Description: Conventional TACE was performed in both groups as follows. First, multiple angiographies were performed to detect the hepatic arterial anatomy and the possible feeding arteries of tumor, selective catheterization of the artery feeding the tumors was performed. A mixture of ethiodized oil was injected, followed by injection of Gelfoam particles.

Intervention type: DEVICE
Intervention: stent; idoine-125
Description: In the ISP-TACE group, stent placement was performed one week before TACE. Under fluoroscopic and ultrasonic guidance, the outer stent was firstly placed at the site of the obstructed portal vein, and a self-expandable nitinol stent was immediately followed through a same 10-F sheath.